Avinger to Announce Full-Year 2021 Results on March 22

Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) will announce its Q4 and full year 2021 financial results after the market closes on March 22, 2022. The company specializes in treating Peripheral Artery Disease (PAD) with its unique intravascular image-guided, catheter-based system. A conference call will follow at 1:30 PM PT / 4:30 PM ET, which can be accessed via telephone or live webcast on Avinger's investor relations page. A recording will be available post-call on their website.

Positive

• Avinger is the first and only company to market an intravascular image-guided system for PAD diagnosis and treatment.
• PAD affects over 12 million people in the U.S. and over 200 million globally, indicating a large market potential.

Negative

• None.

REDWOOD CITY, CA / ACCESSWIRE / March 15, 2022 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2021 after the close of trading on Tuesday, March 22, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.

To join the call by telephone, please dial +1-973-528-0016 and use passcode 754251. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at http://www.avinger.com.

A replay of the webcast will be made available on Avinger's website, www.avinger.com, shortly after completion of the call.

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye^TM family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Follow Avinger on Twitter and Facebook.

Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.

View source version on accesswire.com:
https://www.accesswire.com/693065/Avinger-to-Announce-Full-Year-2021-Results-on-March-22

FAQ

When will Avinger announce its financial results for 2021?

Avinger will announce its financial results for Q4 and the full year 2021 on March 22, 2022.

How can I listen to Avinger's earnings call?

You can listen to Avinger's earnings call by dialing +1-973-528-0016 using passcode 754251 or by accessing the live webcast on Avinger's investor relations page.

What is the significance of Avinger's intravascular system?

Avinger's intravascular system is the first of its kind for the diagnosis and treatment of Peripheral Artery Disease, addressing a significant health issue affecting millions.

Where can I find more information about Avinger, Inc.?

More information about Avinger, Inc. can be found on their official website at www.avinger.com.